Remibrutinib Open Label Roll-over Post-trial Access Protocol

NCT07456891 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Indication of the Parent Protocol

Interventions

DRUG: Remibrutinib

Sponsor

Novartis Pharmaceuticals